Press releases

EVOLVE II trial represents the first successful U.S. pivotal trial of a bioabsorbable polymer stent

System designed for the hysteroscopic removal of interuterine fibroids and polyps

New CPT Category I code facilitates processing for U.S. hospitals and physicians

Boston Scientific will participate in the upcoming healthcare conference on November 18, 2014. A live webcast and replay will be available.

Event will be held in Chicago, site of the 2014 American Heart Association Scientific sessions

Data will focus on long-term back pain relief using the Precision Spectra™ Spinal Cord Stimulator (SCS) System and highlight research on stimulation waveforms

Boston Scientific will participate in the upcoming healthcare conference on November 11, 2014. A live webcast and replay will be available.

"We achieved excellent third quarter results,” said Mike Mahoney, Boston Scientific chairman and CEO

World's first 32-contact SCS surgical leads designed to provide more focused pain relief for patients with chronic pain

PLATINUM diversity trial evaluating performance in women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease

Innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems

Comprehensive clinical data from randomized trials reviewed

Boston Scientific will webcast its conference call discussing financial results and business highlights for Q3 ended September 30, 2014. Learn how to tune in.

Data from REPRISE III clinical trial designed to support U.S. regulatory approval

First DBS system to offer precise neural targeting and a 25-year battery life

No cases of moderate or severe paravalvular aortic regurgitation at one year

Data will focus on areas of significant unmet patient need, including Coronary Artery Disease and Aortic Valve Disease

Boston Scientific will participate in the upcoming healthcare conference on September 17, 2014 in London

Acquisition allows Boston Scientific to offer a more complete portfolio of solutions to treat challenging vascular conditions

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure

Boston Scientific will participate in the healthcare conference on September 8 in New York

Companies reach agreement to develop a new and differentiated FFR guidewire and next generation Boston Scientific Rotablator™ RotaWire™

"We had a strong second quarter, delivering balanced growth across our divisions," said CEO Mike Mahoney

Innovative technology adds to company's leading portfolio of treatment options for Coronary Artery Disease

Easy to use imaging system to support planned intravascular ultrasound and fractional flow reserve products

Advanced bare-metal stent provides additional treatment option for interventional cardiologists and patients

European launch means physicians can now choose from three available valve sizes to match patient anatomy more precisely

Innovative technology strengthens company's leading portfolio of solutions for peripheral vascular disease

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2014. Learn how to tune in.

Data presented at the 18th International Congress of Parkinson's Disease and Movement Disorders demonstrate highly significant improvement in motor function for patients with Parkinson's Disease

Data presented at the International Congress of Parkinson's Disease and Movement Disorders demonstrate superior therapeutic window for the treatment of Parkinson's Disease

Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world

Boston Scientific will participate in the healthcare conference on June 17 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on June 10. Learn how to watch the webcast or replay.

Study evaluated Lotus Valve System in symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement

EVOLVE study data presented today at EuroPCR 2014 also demonstrate excellent safety profile

Boston Scientific reinforces its commitment to global education and innovation

Acquisition expected to strengthen peripheral interventions business and accelerate growth in peripheral atherectomy and thrombectomy categories

PREDICt-RM collaborative study between Boston Scientific, American College of Cardiology and Yale University highlights improved outcomes in ICD and CRT-D patients followed with the LATITUDE™ System.

Boston Scientific Shockless Implant Evaluation (SIMPLE) study results presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th annual scientific sessions.

Advanced Illumina™ 3D Programming Software provides highly significant pain relief in study patients.

Innovative technology designed to treat intrauterine fibroids and polyps.

Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions.

Broad set of data reinforces commitment to advancing research and technology in electrophysiology.

Promising clinical data to be presented at annual conference.

Boston Scientific will participate in the healthcare conference on May 13, 2014. Learn how to watch the webcast or replay.

Advanced drug-eluting stent system recently received Japan Ministry of Health, Labor and Welfare approval.

Company exceeds earnings per share guidance on the strength of continued revenue growth.

Clinical trial is designed to establish the safety and effectiveness of both lead families.

Event will be held in San Francisco, site of the Heart Rhythm Society 35th Annual Scientific Sessions.